Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MEDLEYFRA:3YV 76 EV-to-EBITDA is 13.51 as of Aug. 06, 2026, which is 74% below its 10-year median of 52.29. GuruFocus rates FRA:3YV with a GF Score™ of 76/100 and a GF Value™ of €37.13 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 510 Healthcare Providers & Services companies, MEDLEY ranks worse than 62.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MEDLEY's enterprise value is €388.8 Mil.
MEDLEY's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €28.8 Mil. Therefore, MEDLEY's EV-to-EBITDA for today is 13.51.
The historical rank and industry rank for MEDLEY's EV-to-EBITDA or its related term are showing as below:
FRA:3YV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.66 Med: 52.29 Max: 780.63
Current: 14.28
During the past 7 years, the highest EV-to-EBITDA of MEDLEY was 780.63. The lowest was 12.66. And the median was 52.29.
FRA:3YV's EV-to-EBITDA is ranked worse than 62.16% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 11.07
vs FRA:3YV: 14.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-06), MEDLEY's stock price is €11.50.
MEDLEY's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.181. Therefore, MEDLEY's PE Ratio (TTM) for today is 63.54.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MEDLEY's share price for today is €11.50.
MEDLEY's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.181.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MEDLEY's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3YV vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, MEDLEY's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDLEY EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MEDLEY's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MEDLEY's EV-to-EBITDA falls into.
MEDLEY's current Enterprise Value is €388.8 Mil.
MEDLEY's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDLEY (FRA:3YV) has a EV-to-EBITDA of 13.51 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MEDLEY. This is 74% below median its historical median of 52.29. Over the past decade, MEDLEY's EV-to-EBITDA has ranged from 12.66 to 780.63. According to the industry distribution chart, MEDLEY ranks #317 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 62.2%.
Is MEDLEY's EV-to-EBITDA too high?
MEDLEY's current EV-to-EBITDA of 13.51 is 74% below median its 10-year median of 52.29. Over the past 10 years, this metric has ranged from a low of 12.66 to a high of 780.63. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.07. MEDLEY's value of 13.51 is 22% above this industry median. Based on the distribution chart, MEDLEY ranks #317 out of 510 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MEDLEY has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDLEY's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MEDLEY ranks #317 out of 510 companies for EV-to-EBITDA. This places MEDLEY in the lower half of its industry. The industry median EV-to-EBITDA is 11.07. MEDLEY's value of 13.51 is 22% above this benchmark. Historically, MEDLEY's own EV-to-EBITDA has ranged from 12.66 to 780.63 over the past decade. While the company's 10-year median is 52.29 vs. the industry median of 11.07, MEDLEY has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.07, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDLEY's current EV-to-EBITDA of 13.51 is 22% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MEDLEY. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDLEY's current EV-to-EBITDA is 13.51, which is 74% below median its own 10-year median of 52.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDLEY stock overvalued right now?
Based on GuruFocus' analysis, MEDLEY (FRA:3YV) is currently considered Significantly Undervalued. The stock's GF Value™ is €37.13, compared to a current price of €11.50 — trading 69% below its estimated fair value. The current EV-to-EBITDA is 13.51, which is 74% below median its 10-year median of 52.29 and 22% above the Healthcare Providers & Services industry median of 11.07. MEDLEY's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MEDLEY (FRA:3YV), the current EV-to-EBITDA is 13.51 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDLEY (FRA:3YV) Overvalued in 2026?
Based on GuruFocus' analysis, MEDLEY stock appears to be undervalued.
The current stock price of €11.50 is trading 69% below its estimated GF Value™ of €37.13.
GuruFocus considers MEDLEY to be Significantly Undervalued.
Key valuation signals for FRA:3YV:
EV-to-EBITDA: 13.51 (74% below median its 10-year median of 52.29)
GF Value™: €37.13 vs. price of €11.50 (69% below fair value)
Industry Position: 22% above the Healthcare Providers & Services median (#317 of 510)
No single metric tells the full story. See the FRA:3YV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDLEY Inc is engaged in providing medical information service for patients, and nursing care, a nursing care information service for citizens resolving issues in the field of medical healthcare. It provides its services through two platforms, Recruitment Platform Business which provides human resource recruitment systems in the medical and healthcare field and related businesses; and Medical Platform Business that is a telemedicine system for both patients and medical institutions.
76GF Score
Get the complete analysis for FRA:3YV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3YV has been successfully added to your 
